Camostat Mesilate
Camostat Mesilate is a pharmaceutical drug with 10 clinical trials. Historical success rate of 66.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
7
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
60.0%
6 of 10 finished
40.0%
4 ended early
0
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
The Impact of Camostat Mesilate on COVID-19 Infection
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Camostat With Bicalutamide for COVID-19
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
Camostat Mesylate in COVID-19 Outpatients
Clinical Trials (10)
The Impact of Camostat Mesilate on COVID-19 Infection
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Camostat With Bicalutamide for COVID-19
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
Camostat Mesylate in COVID-19 Outpatients
Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals
Novel Agents for Treatment of High-risk COVID-19 Positive Patients
Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)
Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients
Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10